Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

Aligos Therapeutics, Inc. (ALGS) Stock Forecast 2025 - AI Price Prediction & Analysis

Aligos Therapeutics, Inc. (ALGS) AI Stock Price Forecast & Investment Analysis

Aligos Therapeutics, Inc. (ALGS) - Comprehensive Stock Analysis & Investment Research

Company Overview & Business Profile

Aligos Therapeutics, Inc. (Stock Symbol: ALGS) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry. The organization employs approximately 85 professionals worldwide . The company has established itself as an emerging investment opportunity with substantial growth potential.

Financial Performance & Key Metrics Analysis

Annual Revenue: $3 million generating a -95.7% net profit margin .

Market Capitalization: $96 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -78.3% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Advanced AI Stock Prediction & Price Target Analysis

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Aligos Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Market Position & Competitive Advantage Analysis

Aligos Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities . . The company maintains a healthy 10.1% gross margin, indicating strong pricing power and operational efficiency.

Aligos Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Aligos Therapeutics, Inc. interactive price chart and technical analysis...

Comprehensive Investment Metrics & Financial Analysis - Aligos Therapeutics, Inc. (ALGS)

Deep dive into Aligos Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Aligos Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Aligos Therapeutics, Inc.: With a P/E ratio of -19.24, the market sees the stock as potentially undervalued.

P/E Ratio -19.24x
P/B Ratio 0.94x
Market Cap $96M
EPS $-17.85
Book Value/Share $10.84
Revenue/Share $0.33
FCF/Share $-1.96
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Aligos Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Aligos Therapeutics, Inc.: An ROE of -78.3% indicates room for improvement in shareholder value creation.

ROE -78.3%
ROA -61.2%
ROIC -72.7%
Gross Margin 10.1%
Operating Margin -118.2%
Net Margin -95.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Aligos Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Aligos Therapeutics, Inc.: A current ratio of 4.71 indicates strong liquidity.

Current Ratio 4.71x
Quick Ratio 4.43x
D/E Ratio 0.07x
Financial Leverage 1.38x
Working Capital $220M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Aligos Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Aligos Therapeutics, Inc.: Free cash flow of $-107M indicates cash challenges that need attention.

Operating Cash Flow $-106M
Free Cash Flow $-107M
Capital Spending $-1M
CapEx/Sales 18.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Aligos Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Aligos Therapeutics, Inc.: An asset turnover of 0.03x suggests room for improvement in asset utilization.

Asset Turnover 0.03x
Fixed Assets Turnover 0.4x
Understanding Financial Statement Data

What these metrics mean: Key figures from Aligos Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Aligos Therapeutics, Inc.: With annual revenue of $3M, Aligos Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $3M
R&D Expense $77M
SG&A Expense $485M
Cost of Goods Sold $-4M
Balance Sheet Highlights ($ Millions)
Total Current Assets $93M
Cash & Short-term Investments $87M
Total Liabilities $27M
Dividend & Shareholder Information
Shares Outstanding 9M
Growth Metrics (YoY)
EPS Growth -13.7%

Aligos Therapeutics, Inc. (ALGS) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Aligos Therapeutics, Inc. stock analysis.

Loading Aligos Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Latest Aligos Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Aligos Therapeutics, Inc. (ALGS) stock price and investment outlook.

, source: BioWorld

Aligos Therapeutics Inc. have discovered two novel non-heteroaryldihydropyrimidine (HAP) class A capsid assembly modulators (CAM-A) – ALG-006746 and ALG-006780 – which are being developed for the ...

Aligos Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Aligos Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast $93M -1.9x 0.8x
ABP Unlock Forecast $0M x 0.0x
ABPWW Unlock Forecast $0M x 0.0x
ACLX Unlock Forecast $3725M -74.1x 8.9x
ACOG Unlock Forecast $130M x 4.1x
ADAP Unlock Forecast $91M -13.2x -11.8x
ADMA Unlock Forecast $4374M 20.9x 11.0x
ADPT Unlock Forecast $1977M -4.6x 11.0x
ADVM Unlock Forecast $58M -1.8x 2.2x
AGEN Unlock Forecast $136M -0.5x -0.5x
AIM Unlock Forecast $2M -0.5x -183.3x
AIMI Unlock Forecast $2M x x
ALEC Unlock Forecast $255M -1.2x 3.6x
ALGS Unlock Forecast $96M -19.2x 0.9x
ALLO Unlock Forecast $262M -1.4x 0.8x
ALVR Unlock Forecast $49M -0.5x 0.4x
AMGN Unlock Forecast $158903M 24.0x 21.4x
APGE Unlock Forecast $2241M -20.5x 4.3x
APTO Unlock Forecast $6M 0.0x -1.3x
APTOF Unlock Forecast $3M x x
ARMP Unlock Forecast $97M -1.0x -1.6x
ARTV Unlock Forecast $70M x 0.5x
ATHA Unlock Forecast $16M -0.2x 0.5x
ATRA Unlock Forecast $143M 24.7x -1.1x
ATYR Unlock Forecast $515M -3.6x 6.9x
AURA Unlock Forecast $407M -4.9x 2.3x
AUTL Unlock Forecast $466M x 1.3x
AVXL Unlock Forecast $814M -17.3x 9.0x
BCAB Unlock Forecast $125M -1.1x 1.0x
BCDA Unlock Forecast $12M -0.6x -7.8x
BCLI Unlock Forecast $7M -4.9x -0.9x
BCRX Unlock Forecast $1802M -12.1x -4.0x
BDTX Unlock Forecast $168M 11.6x 1.3x
BEAM Unlock Forecast $1677M -12.6x 1.6x
BIIB Unlock Forecast $18125M 12.8x 1.5x
BKHA Unlock Forecast $0M x 0.0x
BKHAU Unlock Forecast $0M x 0.0x
BLUE Unlock Forecast $49M -0.2x -0.8x
CABA Unlock Forecast $148M -1.6x 0.8x
CADL Unlock Forecast $338M -4.6x 4.5x
CCCC Unlock Forecast $185M -2.6x 1.1x
CDTX Unlock Forecast $728M -1.0x 5.1x
CELZ Unlock Forecast $8M -3.4x 1.2x
CERO Unlock Forecast $3M x -196.2x
CEROW Unlock Forecast $2M x -0.5x
CGEM Unlock Forecast $449M -4.1x 0.8x
CGEN Unlock Forecast $136M x 2.7x
CGON Unlock Forecast $2052M x 3.1x
CGTX Unlock Forecast $183M -0.5x 26.0x
CHRO Unlock Forecast $8M x -2.0x
CHRS Unlock Forecast $143M 0.8x 1.2x
CLDI Unlock Forecast $6M -0.9x 3.3x
CMPX Unlock Forecast $418M -4.8x 4.5x
COEPW Unlock Forecast $M x x
CRBU Unlock Forecast $172M -1.5x 1.0x
CRDF Unlock Forecast $154M -4.0x 2.6x
CRGX Unlock Forecast $215M x 0.9x
CRIS Unlock Forecast $18M -0.3x -2.9x
CRSP Unlock Forecast $4801M -12.1x 2.8x
CSBR Unlock Forecast $111M -17.8x 20.4x
CVM Unlock Forecast $51M -0.9x 7.2x
CYTH Unlock Forecast $26M -0.6x -1.9x
CYTHW Unlock Forecast $7M x -0.5x
DBVT Unlock Forecast $1479M -3.3x 514.8x
DNA Unlock Forecast $568M -13.9x 0.3x
DNLI Unlock Forecast $2111M -8.7x 1.9x
DTIL Unlock Forecast $58M -2.2x 1.7x
DYAI Unlock Forecast $28M -7.3x 11.4x
EDIT Unlock Forecast $231M -0.8x 3.7x
ELEV Unlock Forecast $22M -1.0x 0.5x
ELUT Unlock Forecast $94M -1.4x -0.1x
ENGN Unlock Forecast $221M 3.7x 1.0x
ENGNW Unlock Forecast $37M x 0.1x
ENTX Unlock Forecast $91M 8.5x 5.3x
ENZ Unlock Forecast $25M -3.0x 0.5x
ENZB Unlock Forecast $37M x 0.8x
ESLA Unlock Forecast $36M -3.1x -16.9x
ESLAW Unlock Forecast $4M x 5.3x
EXEL Unlock Forecast $11059M 18.4x 5.4x
EXOZ Unlock Forecast $78M x 10.8x
FATE Unlock Forecast $136M -1.3x 0.5x
FDMT Unlock Forecast $396M -3.0x 0.9x
FENC Unlock Forecast $232M 1758.3x -39.7x
FNCH Unlock Forecast $20M -0.1x 1.4x
FTII Unlock Forecast $-26M x -0.7x
FTIIU Unlock Forecast $-26M x -0.8x
FTIIW Unlock Forecast $0M x 0.0x
GILD Unlock Forecast $144266M 22.9x 7.3x
GLUE Unlock Forecast $400M 16.5x 1.5x
GNTA Unlock Forecast $64M x 5.1x
GPLB Unlock Forecast $M x x
HALO Unlock Forecast $9010M 16.2x 27.1x
HLVX Unlock Forecast $103M -0.6x 0.7x
HUMA Unlock Forecast $247M -3.3x 61.0x
HUMAW Unlock Forecast $163M x -2.6x
IBRX Unlock Forecast $2427M -3.6x -4.1x
IKNA Unlock Forecast $61M -1.3x 0.5x
IKT Unlock Forecast $170M -1.0x 2.1x
IMCR Unlock Forecast $1659M x 4.3x
IMVT Unlock Forecast $2607M -14.5x 4.3x
INAB Unlock Forecast $21M -0.4x 2.4x
INBX Unlock Forecast $387M -6.8x 5.6x
INKT Unlock Forecast $59M -1.5x -1.4x
INMB Unlock Forecast $64M -2.5x 2.2x
INTS Unlock Forecast $8M -2.2x 3.6x
IOVA Unlock Forecast $920M -4.5x 1.3x
IPSC Unlock Forecast $47M -0.7x 0.2x
ITOS Unlock Forecast $393M -2.8x 0.7x
IVVD Unlock Forecast $62M -0.4x 1.5x
IZTC Unlock Forecast $99M x -27.5x
JSPR Unlock Forecast $48M -3.2x 2.0x
JSPRW Unlock Forecast $3M x 0.0x
KLRS Unlock Forecast $47M x 0.9x
KLTO Unlock Forecast $39M x 3.7x
KLTOW Unlock Forecast $1M x 0.4x
KOD Unlock Forecast $539M -2.5x 7.7x
KRBPQ Unlock Forecast $0M x x
KRYS Unlock Forecast $4487M 30.6x 4.3x
KYMR Unlock Forecast $3541M -17.8x 3.7x
KYTX Unlock Forecast $166M x 0.9x
LADX Unlock Forecast $M x x
LCTX Unlock Forecast $267M -4.7x 5.5x
LENZ Unlock Forecast $1140M -6.7x 5.5x
LIMN Unlock Forecast $0M x x
LXEO Unlock Forecast $265M -0.4x 1.9x
MAZE Unlock Forecast $592M x 2.3x
MGTX Unlock Forecast $693M -3.4x 20.9x
MGX Unlock Forecast $72M x 0.4x
MRNA Unlock Forecast $10550M -3.2x 1.1x
NBIX Unlock Forecast $13787M 39.6x 5.1x
NKGN Unlock Forecast $4M -0.1x -0.2x
NKGNW Unlock Forecast $1M x 0.0x
NMRA Unlock Forecast $262M -3.9x 1.4x
NVAX Unlock Forecast $1391M 3.3x 37.0x
OCGN Unlock Forecast $298M -4.3x 18.7x
OMGA Unlock Forecast $9M -0.7x 0.8x
OMGAQ Unlock Forecast $0M x 0.0x
ONVO Unlock Forecast $35M -0.4x 95.9x
OTLK Unlock Forecast $73M -0.2x -2.3x
PALI Unlock Forecast $4M -0.2x 0.7x
PASG Unlock Forecast $24M -0.6x 0.6x
PCVX Unlock Forecast $4387M -20.4x 1.4x
PHGE Unlock Forecast $15M 1.5x 0.8x
PLUR Unlock Forecast $-5M -1.4x -9.1x
PLX Unlock Forecast $129M 20.5x 2.6x
PMCB Unlock Forecast $7M -2.6x 0.2x
PRME Unlock Forecast $477M -1.5x 7.8x
PROK Unlock Forecast $-68M x 0.0x
PSTX Unlock Forecast $926M -9.6x 10.6x
PTHS Unlock Forecast $M x x
QGEN Unlock Forecast $11177M x 3.1x
QNCX Unlock Forecast $87M -1.7x 7.5x
REPL Unlock Forecast $932M -3.8x 2.2x
RGEN Unlock Forecast $6531M 8219.1x 3.3x
RGNX Unlock Forecast $463M -1.8x 2.2x
RLAY Unlock Forecast $634M -2.0x 1.0x
RVMD Unlock Forecast $7134M -11.1x 3.4x
RVMDW Unlock Forecast $16M x 0.0x
RXRX Unlock Forecast $2138M -4.7x 2.3x
SABS Unlock Forecast $24M -2.3x 1.1x
SABSW Unlock Forecast $0M x 0.0x
SANA Unlock Forecast $852M -2.1x 7.0x
SCLX Unlock Forecast $62M -0.4x -0.3x
SCLXW Unlock Forecast $25M x -0.1x
SCNI Unlock Forecast $5359M -287.8x -2577.2x
SGMO Unlock Forecast $141M -1.6x 7.2x
SLDB Unlock Forecast $495M -0.9x 1.7x
SLXN Unlock Forecast $4M x 34.7x
SLXNW Unlock Forecast $866M x -189.1x
SNTI Unlock Forecast $51M -1.1x 1.3x
SRRK Unlock Forecast $4069M -18.5x 13.0x
SRZN Unlock Forecast $98M -0.5x 2.1x
SRZNW Unlock Forecast $0M x 0.0x
STRO Unlock Forecast $73M -1.0x -2.5x
SWTX Unlock Forecast $3539M -9.9x 8.5x
TARA Unlock Forecast $129M -2.1x 0.9x
TARS Unlock Forecast $2417M -12.4x 7.3x
TCBP Unlock Forecast $37M x 34.5x
TCBPW Unlock Forecast $1M x 1.0x
TCBPY Unlock Forecast $21M x 19.1x
TCRX Unlock Forecast $243M -4.6x 1.4x
TECH Unlock Forecast $8155M 75.2x 4.0x
TECX Unlock Forecast $490M -8.9x 1.7x
TIL Unlock Forecast $182M -1.1x 1.3x
TNYA Unlock Forecast $154M -2.5x 1.5x
TRML Unlock Forecast $600M -3.5x 2.3x
TSBX Unlock Forecast $8M -0.1x 0.6x
TSHA Unlock Forecast $851M -3.0x 3.4x
TTNP Unlock Forecast $8M -0.5x 4.5x
TVGN Unlock Forecast $181M x -29.3x
TVGNW Unlock Forecast $11M x -1.9x
TWST Unlock Forecast $1720M -12.6x 3.6x
VACH Unlock Forecast $-1436M x 0.0x
VACHU Unlock Forecast $-1585M x 0.0x
VCEL Unlock Forecast $1868M 262.8x 6.1x
VIGL Unlock Forecast $384M -1.1x 9.3x
VIR Unlock Forecast $636M -2.0x 0.7x
VIVS Unlock Forecast $3M x 0.3x
VOR Unlock Forecast $273M -0.6x 3.9x
VXRT Unlock Forecast $80M -0.9x 2.4x
VYGR Unlock Forecast $201M 570.6x 0.8x
WINT Unlock Forecast $18M -0.4x 4.2x
XFOR Unlock Forecast $8M 6.4x 0.4x
ZIVO Unlock Forecast $70M -31.3x -2.0x
ZURA Unlock Forecast $131M 5.0x 0.9x

Frequently Asked Questions - Aligos Therapeutics, Inc. Stock Forecast

How accurate are Aligos Therapeutics, Inc. stock predictions?

Our AI model demonstrates 64% historical accuracy for ALGS predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Aligos Therapeutics, Inc. stock price forecasts?

Our analysis considers Aligos Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Aligos Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Aligos Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Aligos Therapeutics, Inc. forecasts updated?

Aligos Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Aligos Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Aligos Therapeutics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...